A new treatment approach for lung cancer that resists current therapies
Official title: Hi-jacking the kynurenine pathway: A new therapeutic approach used to treat cisplatin resistant lung cancer that evades immune surveillance and proliferates with increased ROS levels
Funded at Miami VA Health Care System · NIH-11050121 · Data updated 2026-11-12
This study is looking at a new way to help people with non-small cell lung cancer that doesn't get better with standard treatments, by understanding how some cancer cells hide from the immune system and finding better ways to fight them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Miami VA Health Care System NIH-funded |
| Lab location | 1 site (Miami, United States) |
| Project start | July 1, 2018 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| NIH project number | 2I01BX004371-05A2 |
| Project ID | NIH-11050121 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have shown resistance to cisplatin-based therapies.
✕Less likely to help
Patients with lung cancer that is sensitive to cisplatin or those with other types of cancer may not benefit from this research.
What this research studies
This research investigates a novel therapeutic strategy targeting the kynurenine pathway to treat lung cancer that is resistant to cisplatin and evades immune detection. The study focuses on understanding how certain cancer cells manipulate their environment to avoid immune responses, particularly through the activity of specific proteins like IDO1 and YAP1. By analyzing these mechanisms, the researchers aim to develop more effective treatments for patients with non-small cell lung cancer (NSCLC) who do not respond to existing therapies.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with resistant lung cancer, potentially increasing survival rates.
How similar studies have gone: Previous research has shown promise in targeting immune evasion mechanisms in cancer, suggesting that this approach could be effective, although it is still considered novel.
Where this research is happening
-
Miami VA Health Care System
Miami, United States Active
Researchers
- Principal investigator: Wangpaichitr, Medhi — Miami VA Health Care System
- Study coordinator: Wangpaichitr, Medhi
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.